COPD Plasma

About COPD Plasma

COPD Plasma for Chronic Airway Inflammation Research

COPD Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of chronic obstructive pulmonary disease and processed within one day of collection to preserve labile analytes such as cytokines, proteases, proteins and metabolites. Plasma is acellular, so this product is supplied for soluble-analyte work — multiplex immunoassay, protease activity measurement, proteomics and metabolomics — in standard or custom aliquot volumes with de-identified clinical annotation.

Why COPD Plasma for Airway Inflammation Research

COPD is a chronic inflammatory airway disease, not an autoimmune one. Long-term inhalational injury, most often from tobacco smoke or biomass exposure, drives persistent neutrophil and macrophage recruitment into the airways and lung parenchyma. Oxidative stress amplifies that response, and the resulting imbalance between proteases and their inhibitors degrades elastin and other structural matrix, producing emphysema and irreversible airflow limitation. This local process spills over into the circulation as measurable systemic inflammation.

• Neutrophilic and macrophage inflammation — IL-8/CXCL8 and other neutrophil chemoattractants, along with macrophage-derived mediators, reflect the dominant cellular infiltrate in COPD airways.
• Protease-antiprotease imbalance — neutrophil elastase, matrix metalloproteinases including MMP-9 and MMP-12, and their inhibitors are the mechanistic link between inflammation and matrix destruction.
• Alpha-1 antitrypsin biology — the principal physiological inhibitor of neutrophil elastase is a circulating plasma protein, making plasma the natural matrix for antiprotease work.
• Oxidative stress markers — products of lipid and protein oxidation and shifts in antioxidant capacity are measurable in the acellular compartment.
• Systemic inflammatory and matrix-turnover mediators — CRP, fibrinogen, IL-6 and TNF-α, together with elastin and collagen degradation fragments, characterise the systemic component of the disease.
• Comorbidity and exacerbation biology — cardiovascular, metabolic and cachexia-associated analytes travel in plasma and are central to understanding why COPD outcomes extend beyond the lung.

Donor Stratification Available

• Airflow limitation severity — donors graded by spirometry-based severity classification where documented
• Clinical phenotype — emphysema-predominant, chronic bronchitis-predominant, and mixed presentations
• Exacerbation history — frequent exacerbators versus stable donors, and samples drawn during exacerbation versus at stable state
• Alpha-1 antitrypsin deficiency status — donors with documented deficiency available as a distinct subgroup
• Smoking status and exposure history — current smokers, former smokers, and never-smokers with occupational or biomass exposure; treatment status including inhaled bronchodilator, inhaled corticosteroid, and biologic therapy
• Matched healthy controls available, including smoking-matched controls without airflow limitation

Product Features

• Research Use Only (RUO)
• COPD plasma collected from clinically confirmed donors
• Processed within one day of collection
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request
• Volumes and anticoagulant options reported per lot

De-identified Donor Data

• Verified COPD diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Severity, smoking history and exacerbation context reported per lot where captured
• Additional COPD-specific metadata available on request

Applications

• Neutrophil chemokine and inflammatory mediator quantification
• Neutrophil elastase and matrix metalloproteinase activity assay development
• Alpha-1 antitrypsin quantification, function and augmentation-therapy research
• Oxidative stress and antioxidant capacity marker profiling
• Extracellular matrix turnover and elastin degradation fragment studies
• Exacerbation biomarker discovery and stable-versus-exacerbation comparison
• Plasma proteomic and metabolomic discovery in chronic airway disease
• Systemic comorbidity and cachexia marker research in COPD cohorts

Other COPD Specimen Types

• COPD Serum
• COPD Bulk Plasma
• COPD PBMC
• COPD Whole Blood
• COPD Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

COPD plasma is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human plasma page.